Literature DB >> 8220440

Debrisoquine and metoprolol oxidation in Zambians: a population study.

O O Simooya1, E Njunju, A R Hodjegan, M S Lennard, G T Tucker.   

Abstract

The 0-8 h urinary distributions of the metabolic ratios of debrisoquine (10 mg) and metoprolol (100 mg) were measured in 102 healthy, unrelated, black Zambian medical students. There was a statistically significant correlation (rs = 0.60, p < 0.001; n = 88) between the debrisoquine/4-hydroxydebrisoquine (D/HD) and metoprolol/alpha-hydroxymetoprolol (M/HM) ratios. Bimodality in the distribution of the log10D/HD ratio was not evident from visual inspection and following kernel density analysis of the data, although two subjects (ratios 20, 22) would be classified as phenotypic poor metabolizers (PMs) based on the antimode used for Caucasian populations. The distribution of the log10M/HM ratio was skewed and on the basis of kernel density analysis, bimodal. It was clear from visual inspection of the data that the very high M/HM value (> or = 302) of one individual had a profound influence on the population M/HM ratio distribution. No HM was detected in the urine of this subject but he was not one of the two PMs of debrisoquine (D/HD ratio 1.54). H117/04, the major metabolite of metoprolol was also not detected in this sample. Since H117/04 was shown to be present in all samples from previous population studies, the possibility that this subject did not comply with the protocol could not be excluded. All other subjects had M/HM ratios < or = 12.5. These findings suggest that there is a dissociation in the control of debrisoquine and metoprolol oxidation in Zambians as has been observed previously in Nigerians. Furthermore, clear evidence that the metabolism of these drugs exhibits genetic polymorphism in Zambians was not obtained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220440     DOI: 10.1097/00008571-199308000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  6 in total

1.  Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.

Authors:  A Bozkurt; N E Basçi; A Işimer; A Sayal; S O Kayaalp
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

Review 2.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

3.  Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.

Authors:  A Gaedigk; A Bhathena; L Ndjountché; R E Pearce; S M Abdel-Rahman; S W Alander; L DiAnne Bradford; P K Rogan; J Steven Leeder
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

4.  Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.

Authors:  Y M Irshaid; H F al-Hadidi; A Latif; F Awwadi; M al-Zoubi; N M Rawashdeh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

5.  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.

Authors:  H F al-Hadidi; Y M Irshaid; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.